Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
FierceBiotech5h
Entrada’s 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Nasdaq21d
Entrada Therapeutics Authorizes Phase 1/2 Clinical Trial for ENTR-601-44 to Treat Duchenne Muscular Dystrophy, On Track for Q2 2025 Initiation
Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...
Nasdaq21d
ENTR-601-44 Trial For DMD Authorized In UK, Study Launch Expected In Q2 2025
(RTTNews) - Entrada Therapeutics, Inc. (TRDA), a clinical-stage biopharmaceutical company, on Monday provided an update on its upcoming Phase 1/2 clinical trial for ENTR-601-44, a treatment for ...
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...
Managed Healthcare Executive12d
Entrada Therapeutics On Track For New DMD Study in the U.K.
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Hosted on MSN21d
Entrada Therapeutics advances Duchenne treatment study
ENTR-601-44 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO) designed to restore the mRNA reading frame and allow for the production of a ...
Hosted on MSN20d
Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment
Entrada Therapeutics CEO Dipal Doshi said: “As the first authorisation for our global MAD clinical study of ENTR-601-44 in patients, we are pleased to be initiating the study at what we believe ...
Entrada announces FDA removal of clinical hold on ENTR-601-44
Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...
Investing21d
Entrada Therapeutics advances Duchenne treatment study
BOSTON - Entrada Therapeutics , Inc. (NASDAQ:TRDA) received authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial for its ...